The era of targeted therapy for hyperlipidemia
| Autor: | U. V. Chubykina, A. V. Tyurina, M. V. Ezhov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Российский кардиологический журнал, Vol 29, Iss 8 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1560-4071 2618-7620 |
| DOI: | 10.15829/1560-4071-2024-6038 |
| Popis: | Despite a variety of lipid-lowering drugs, mostly pelleted, aimed at reducing low-density lipoprotein cholesterol and triglycerides, only a small number of patients achieve their target levels. The reasons are insufficient adherence to treatment, rare use of combined lipid-lowering therapy regimens by attending physicians, low availability and high cost of injected lipid-lowering agents. With the advent of technologies for targeted therapy for hyperlipidemia, a new era in cardiology opens. These innovations will lead to higher goal achievement rates through a personalized and precision approach to hyperlipidemia treatment. Novel lipid-lowering drugs are directed at the molecular targets of hypercholesterolemia, hyperlipoproteinemia(a) and hypertriglyceridemia. The review purpose is to systematize following information about innovative lipid-lowering drugs: mechanism of action, stage of development, effectiveness and safety. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|